Please login to the form below

Focus on immunotherapies: special magazine from Blue Latitude Health

Blue Latitude Health have worked with four of the eight immunotherapies currently approved by the FDA, so we've pooled our expertise across the different capabilities to give you a clear view on the fourth pillar of care in oncology.
As a creative marketing consultancy, we have a unique perspective on the challenges facing the broad range of stakeholders in the healthcare and pharma industry. As such, we've created this magazine to explore those challenges in depth from a variety of viewpoints.

In this supplementary issue, we’re taking a special look at immunotherapies, and more specifically, the growing buzz around “immuno-oncology” therapies. At the time of publication, Blue Latitude Health have worked with four of the eight immunotherapies currently approved by the FDA, so we've pooled our expertise across the different capabilities to give you a clear view on the fourth pillar of care in oncology. 


The immunotherapy special issue covers:

  • Immunology in oncology as a therapy area – what it is, how it works, and where it’s heading from a medical and commercial point of view.
  • Key insights around positioning immuno-oncology products based on our hands-on experience working in this area.
  • What new immunotherapies in oncology mean for cancer patients and the doctors who would prescribe them, and in turn, what that means for pharma.
  • The immuno-therapy patient experience as a customer journey.

Download the magazine from Blue Latitude Health

20th May 2016

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

Fishawack Health launches global ‘PsoriasIS NOT CONTAGIOUS’ mask campaign for World Psoriasis Day 2020
Fishawack Health launches global disease awareness campaign, supported by the community of Psoriasis Warriors to de-stigmatize psoriasis during the COVID-19 pandemic.
Blue Latitude Health
Fishawack Health, a new breed of global commercialization partner, fit for a post pandemic world
Our parent company, Fishawack Health has reorganized to deliver agile and innovative solutions for life-sciences companies in the face of rapidly changing markets
Blue Latitude Health
In the precision medicine era, the line between products and services is blurred
Precision and personalised medicines are more than products, they are services in their own right. So, how should pharma approach this uncharted territory to ensure targeted therapies work for patients?
Blue Latitude Health
Understanding COVID-19 and varying responses across the globe
At the beginning of the COVID-19 Pandemic, Senior Account Executive Lauren Fernandes took a course at the London School of Hygiene and Tropical Medicine to better understand how the global response to the virus and to ensure we were best positioned to serve our clients during this challenging time. She shares the key learnings and why understanding the epidemiology of the disease is integral for fighting it.
Blue Latitude Health
Top 5 tips for a multi-indication product launch
Senior Associate Consultant Sana Rahim and Senior Consultant Victoria Clark explain the lessons the team has learned from launching six different indications of an oncology product in an accelerated timeframe.
Blue Latitude Health
If our patients are diverse, why are clinical trials so white?
Despite facing worse health outcomes, minority populations are often left out of clinical trials and miss the opportunity to participate in life-saving research. Associate Consultant Ling Song explores this issue and calls for the pharmaceutical industry to change its approach.
Blue Latitude Health